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ATCC   American type culture collection 
BHI  Brain Heart Infusion 
CFU  colonyforming unit 
CLSI  Clinical and Laboratory Standards 
Institute 
DMF  N,N-dimethylformamide 
DMSO  dimethyl sulfoxide 
GyrA  DNA gyrase A subunit 
GyrB  DNA gyrase B subunit 
IM  inner membrane 
HEPES 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid 
LB  Lysogeny Broth 
MBC  minimum bactericidal concentration 
MH  Mueller Hinton 
MIC  minimum inhibitory concentration 
ONPG  ortho-nitrophenyl-β-galactoside 
ParC  topoisomerase IV subunit A 
ParE  topoisomerase IV subunit B 
PaβN phenylalanine-arginine β-
naphthylamide 
TRIS  tris(hydroxymethyl) aminomethane 




• Synthesis of quaternary ammonium fluoroquinolones. 
• In vitro evaluation against a panel of Gram-positive and negative bacterial strains. 
• Efflux, cellular accumulation, resistance, membrane permeabilization, cytotoxicity. 
• E. coli DNA gyrase inhibition evaluation. 
• DNA gyrase and topoisomerase molecular docking. 
 
Abstract 
A series of novel fluoroquinolone-Safirinium dye hybrids was synthesized by means of tandem 
Mannich-electrophilic amination reactions from profluorophoric isoxazolones and antibiotics 
bearing a secondary amino group at position 7 of the quinoline ring. The obtained fluorescent 
spiro fused conjugates incorporating quaternary nitrogen atoms were characterized by 1H 
NMR, IR, MS, and elemental analysis. All the synthetic analogues (3a-h and 4a-h) were 
evaluated for their in vitro antimicrobial, bactericidal, and antibiofilm activities against a panel 
of Gram positive and Gram-negative pathogenic bacteria. The most active Safirinium Q 
derivatives of lomefloxacin (4d) and ciprofloxacin (4e) exhibited molar-based antibacterial 
activities comparable to the unmodified drugs and displayed considerable inhibitory potencies 
in E. coli DNA gyrase supercoiling assays with IC50 values in the low micromolar range. 
Zwiterionic hybrids were noticeably less lipophilic than the parent quinolones in micellar 
electrokinetic chromatography (MECK) experiments. The tests performed in the presence of 
phenylalanine-arginine β-naphthylamide (PAβN) or carbonyl cyanide m-chlorophenyl- 
hydrazone (CCCP) revealed that the conjugates are to some extent subject to bacterial efflux 
and cellular accumulation, respectively. Moreover, the hybrids did not exhibit notable 
cytotoxicity towards the HEK 293 control cell line and demonstrated low propensity for 
resistance development, as exemplified for compounds 3g and 4b. Finally, molecular docking 
experiments revealed that the synthesized compounds were able to bind in the fluoroquinolone-
binding mode at S. aureus DNA gyrase and S. pneumoniae topoisomerase IV active sites. 
 
1. Introduction 
Since the disclosure of nalidixic acid by George Lesher in 1962 [1] more than ten thousands congeners 
have been obtained from which four generations of bactericides with broad spectrum of antibacterial 
activities have been developed [2]. Quinolone chemotherapeutics target and inhibit the action of 
homologous type II topoisomerases, DNA gyrase and DNA topoisomerase IV [3]. The quinolone 
inhibition mechanism has been extensively studied on molecular level. A crystal structure of 
moxifloxacin in complex with topoisomerase IV demonstrates the quinolone bound by chelation to a 
noncatalytic magnesium ion and wedged between base pairs at the DNA cleavage site [4]. 
Fluoroquinolones are amphoteric compounds that exist as zwitterionic, cationic, anionic and neutral 
species at physiological pH conditions [5]. The neutral forms are more lipophilic than the zwitterionic 
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species. The lipophilicity of the fluoroquinolones plays an essential role in their penetration into 
bacterial cells [6]. It is well-known that introduction of a N-Mannich base functional group can 
decrease protonation of the parent amine at physiological pH resulting in an increase of lipophilic 
properties of a compound and in consequence improvement of its ability to penetrate through bio-
membranes [7]. It has been established that fluoroquinolones permeate to the cells of Gram-positive 
bacteria through passive diffusion, however it is assumed that only the neutral species of these 
compounds can penetrate across the cytoplasmic membranes [8,9]. Conversely, in the case of Gram-
negative bacteria, fluoroquinolones are supposed to penetrate the bacterial cells mainly through the 
hydrophilic way by means of porine channel, and to a lesser extent by the hydrophobic route across 
the lipid bilayer [10,11]. Consequently, the more hydrophobic a compound is, the better it penetrates 
through lipid bilayer whilst the adverse is true for the diffusion through hydrophilic porin channels. 
Compared to drugs targeting human cells, antibacterial drugs demonstrate higher molecular weights, 
lower lipophilicity, and larger total polar surface areas. Hence, majority of the antibacterial agents do 
not comply with Lipinski's “rule of 5”, which specify the most favorable drug-like attributes. 
Antibacterial compounds have always been considered an exemption to these principles indicating a 
requirement of divergent properties for the penetration into nonhuman cells [12]. 
Structure–activity relationship (SAR) investigations of fluoroquinolones have proved that the basic 
group at the C-7 position, the only position that substitution of bulky functional group is permitted, 
significantly affects their antibacterial spectrum, potency, and safety [13]. Moreover, introduction of 
increased bulkiness at the C-7 site may contribute to protection against bacterial efflux pumps, and 
diminish the prospect of antibiotic resistance development of typical bacterial strains [[14], [15], 
[16]]. 
Central nervous system (CNS) effects represent one of the most common group of quinolone adverse 
events, including headache, dizziness, agitation, sleep disorders and in rare instances convulsions. It 
was suggested that there is a structural analogy between γ-aminobutyric acid (GABA) and the 
piperazinyl and pyrrolidinyl side chains present in most quinolones. Unsubstituted piperazines show 
the greatest binding, however predicting overall CNS liability from GABA inhibition data alone is 
inefficient, because in-vivo penetration to the brain is also an important variable. As a first 
approximation, one might assume that quinolones with the highest overall lipophilicity would have 
the greatest penetration into the CNS and brain. Then the quinolones with the least CNS toxicity 
would be predicted to be those with bulky C7 substituents (low GABA binding) and low overall 
lipophilicity (lower brain penetration). Nevertheless, since relatively few studies determining 
quinolone lipophilicity (log P) over a wide range of structures have been published, predicting direct 
CNS effects for the quinolones is still difficult [17]. 
Hybridization constitute a convenient method for the development of new drugs with the capability 
to reduce cross resistance, counterbalance the known side effects associated with the other hybrid part 
or improve affinity and efficacy compared with the parent drugs. A number of successful approaches 
to hybrid drugs on the basis of fluoroquinolones have been reported [[18], [19], [20], [21], [22], [23], 
[24], [25], [26], [27]]. Numerous works have been conducted toward the synthesis of quinolone 
hybrids that combine diverse types of bioactive molecules including aminoglycosides [28], 
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macrolides [29], oxazolidinones [30], isatin [31], benzofuroxan [32] etc. into the C-7 position to 
obtain drug conjugates, which have shown great potential as novel antimicrobial agents. 
Herein, we report the synthesis of hybrid compounds for the purpose of modification of the 
physicochemical properties of fluoroquinolones and/or synergistic effect through combining 
piperazinyl quinolones and quaternary ammonium salts (QACs) [33] in one compact structure. The 
main objective of the project was to design and prepare a series new dual acting hydrophilic 
antibacterials incorporating a fluoroquinolone drug and a fluorescent triazolinium compound with 
proved antibacterial properties, aimed at evaluating the hypothesis that a new class of hybrid 
antibacterial agents can be obtained that exhibit an unique dual antimicrobial mechanism of action: 
(i) perturbation of the lipid bilayer of the bacterial cytoplasmic membrane and the outer membrane 
of Gram-negative bacteria due to presence of quaternary ammonium group, and (ii) inhibition of 
DNA gyrase/bacterial topoisomerase IV elicited by fluoroquinolone portion. Fluorescent properties 
of these hybrid agents would allow the evaluation of their penetration into the bacterial cell. 
 
2. RESULTS AND DISCUSSION 
2.1. Chemistry 
Recently, in our laboratories a new tandem Mannich – electrophilic amination reaction has been 
discovered, that have led to fluorescent triazolinium salts (Safirinium) [34]. Hence, treatment of 
isoxazolo[3,4-b]pyridin-3(1H)-one [35] or isoxazolo[3,4-b]quinolin-3(1H)-one [36] with secondary 
amines in the presence of formaldehyde gave rise to the formation of two series of fluorescent dyes: 
Safirinium-P (pyridine core) and Safirinium-Q (quinoline core), that feature high quantum yields of 
fluorescence, very good solubility in water and large Stoke's shifts [34,36]. It is well known that a 
large number of fluoroquinolone antibacterial drugs feature a secondary aliphatic amino group in 
their structure, i.e. piperazinyl or piperidinyl groups (Scheme 1). This prompted us to subject a series 
of (fluoro)quinolones bearing secondary amino group at position 7 to the tandem Mannich – 







                                       Scheme 1. Synthesis of hybrid compounds 3a-h and 4a-h. 
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Quinolone antibiotics subsequently employed to the coupling reactions belong to four 
fluoroquinolone generations: I – pipemidic acid (a); II – enoxacin (b), norfloxacin (c), lomefloxacin 
(d), and ciprofloxacin (e); III – sparfloxacin (f); IV – gatifloxacin (g) and moxifloxacin (h). Thus, the 
reaction of isoxazolones 1 and 2 with the corresponding fluoroquinolones in the presence of 
formaldehyde resulted in formation of library of quaternary hybrid compounds linked directly at the 
basic piperazine or piperazine amine groups. The obtained conjugates in the forms of inner salts were 
transformed into hydrochlorides upon acidification with HCl methanol solution aiming to increase 
the solubility of the products. Cream-colored solid compounds 3a-e,g,h and 4a-f were purified by 
crystallization, while sparfloxacin derivative 3f was isolated by means of a preparative HPLC. 
Safirinium P derivatives 3a-h were obtained in fair yields (20–72%), while Safirinium Q conjugates 
4a-h were afforded in good to excellent yields (73–93%). Due to the presence of quaternary nitrogen 
atom in trazolinium ring, an asymmetric center was formed in case of derivatives bearing chiral 
carbon atoms within cyclic amine ring. Sparfloxacin and moxifloxacin were used for reaction as pure 
isomers with known absolute configurations and their derivatives 3f,h, 4f,h were obtained as 1:1 
mixtures of two diasereoisomers as evidenced in the NMR experiments. Lomefloxacin and 
gatifloxacin bearing methyl substituent within the piperazynyl ring were used as a mixture of 
enantiomers, therefore the coupling reactions resulted in the formation of derivatives 3d,g and 4d,g 
in the forms of two diastereomers/enantiomers pairs. The corresponding optical isomers were not 
isolated and hence they were used in further biological evaluations as mixtures. 
2.2. Lipophilicity 
Lipophilic properties were determined with use of micellar electrokinetic chromatography (MECK). 
Aqueous micelle solution, above the critical micelle concentration (CMC) filled the capillary in 
MEKC and formed pseudostationary phase [37]. Briefly, the concept of application of MEKC in 
order to determine lipophilicity is based on different affinity to the pseudostationary phase [38]. 
Target compounds interact with micelles and migrate dissolved in the aqueous phase according to 
their lipophilicity. The more lipophilic the analyte is, the stronger it binds to the micelles and in 
consequence migrates toward the cathode with lower velocity. The migration data are expressed by 
the retention factor (log k MECK). Several studies showed correlation between log k MECK and 
classical log P values determined by the shake flask method, which proves the effectiveness of MECK 
in lipophilicity determination [[38], [39], [40], [41]]. The results of the MECK lipophilicity 
assessments are listed in Table 1. As expected the newly synthesized Safirinium-quinolone hybrids 
were found to be considerably less lipophilic than the parent fluoroquinolones. Hence, the two non-
fluorinated pipemidic acid derivatives 3d and 4a proved the most hydrophilic character within the 
series. Furthermore, significantly lower log k values were determined for Safirinium P hybrids 3 in 
comparison to their Safirinium Q counterparts 4. The obtained data also showed that sparfloxacin 
derivative 4f incorporating two fluorine atoms, 3,5-dimethylpiperazinyl group and quinoline core was 





Table 1. Log k and σ log k values obtained in MEKC experiments. 
Compound   log k σ log k 
a −0.5725 0.0021 
4a −0.4434 0.0003 
Pipemidic acid −0.1697 0.0044 
3b −0.3984 0.0027 
4b −0.2387 0.0009 
Enoxacin 0.1564 0.0070 
3c −0.2721 0.0012 
4c −0.1044 0.0057 
Norfloxacin 0.1033 0.0049 
3d −0.4791 0.0039 
4d −0.2650 0.0020 
Lomefloxacin 0.0766 0.0003 
3e −0.3214 0.0117 
4e −0.1527 0.0007 
Ciprofloxacin 0.1039 0.0011 
3f −0.2606 0.0070 
4f −0.0700 0.0041 
Sparfloxacin 0.1161 0.0005 
3g −0.4080 0.0175 
4g −0.1255 0.0036 
Gatifloxacin 0.1010 0.0012 
3h nt nt 
4h −0.2502 0.0036 
Moxifloxacin 0.1083 0.0001 
 
2.3. Antibacterial activity 
The obtained hybrid compounds as well as the unmodified quinolones were tested against a panel of 
Gram-positive and Gram-negative bacterial strains. Despite higher molecular weight than parent 
drugs, most of the designed molecules retained the activity against both Gram-positive and Gram-
negative microorganisms. MIC and MBC values are summarized in Table 2. In general, Safirinium 
Q derivatives 4 exhibited higher activity than the corresponding Safirinium P analogues 3. In most 
cases MIC values determined for the hybrids expressed in μg/mL were at least twice higher than these 
established for the parent drugs. However, despite an approximate doubling the molecular weight 
relative to the parent quinolones, the molar-based antibacterial activities of the conjugates were 
comparable to the unmodified drugs. For example, enoxacin derivative 4b reached minimal inhibitory 
concentration of 0.25 μg/mL against P. vulgaris along with 1 μg/mL against E. coli and 
P. aeruginosa. Lomefloxacin derivative 4d was also found to be highly potent against above strains 
with MIC values of 0.25, 0.25, and 1 μg/mL, respectively. This compound exhibited the same activity 
as free lomefloxacin against P. aeruginosa. Moreover, it was effective against B. subtilis (MIC of 
0.5 μg/mL). Hybrids 4d and 4e exhibited strong activity of 1 μg/mL against S. epidermidis clinical 
isolate. Ciprofloxacin conjugate 4e showed remarkable activity against E. coli (MIC of 2 μg/mL) and 
P. vulgaris (MIC of 0.063 μg/mL) laboratory strains. The later microorganism was found to be the 
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most susceptible to the obtained hybrids with MIC values of 0.125 μg/mL for compound 4d, 
0.25 μg/mL for 4b and 3c, 0.5 μg/mL for 3g,h, and 1 μg/mL for 3b,d,f. MIC values of the obtained 
conjugates are no more than fourfold higher than their MBC values, therefore these fluoroquinolone 





















Table 2. MIC and MBC values determined for compounds 3a-h and 4a-h as well as their parent compounds.
Compound 
MIC/MBC [μg/mL] 
































3a >512 >512 >512 >512 >512 >512 >512 256/>512 >512 >512 >512 >512 
4a 512/512 512/512 256/256 >512 64/64 16/16 128/128 16/16 256/256 8/16 >512 128/128 
Pipemidic 
acid 
64/128 32/32 32/32 >512 2/2 2/2 8/8 0.004/0.004 32/32 32/64 >512 2/2 
3b 128/128 128/128 128/128 16/32 16/16 8/16 512/512 1/2 128/128 64/128 >512 64/128 
4b 8/8 8/8 4/4 512/512 2/2 1/2 1/1 0.25/0.5 4/16 2/2 256/512 8/16 
Enoxacin 1/1 1/1 0.5/2 64/64 0.125/0.125 0.25/0.5 0.5/0.5 0.032/0.063 0.5/1 0.25/0.25 32/>512 0.25/0.25 
3c 64/128 128/128 64/128 >512 16/64 4/8 256/>512 0.25/0.5 64/128 32/32 >512 64/128 
4c 64/64 64/64 32/32 >512 16/16 4/4 64/64 2/2 32/32 64/64 >512 32/32 
Norfloxacin 0.25/0.25 1/2 0.5/2 64/64 0.125/0.125 0.032/0.063 0.25/0.25 0.016/0.016 1/1 0.125/0.125 128/>512 0.25/0.25 
3d 64/64 128/128 32/64 >512 8/8 4/8 128/>512 1/1 128/128 16/32 >512 64/64 
4d 2/2 2/2 4/4 512/512 0.5/0.5 0.25/0.5 1/1 0.125/0.125 4/16 1/2 512/512 2/2 
Lomefloxacin 1/1 0.5/1 1/2 128/128 0.125/0.125 0.063/0.125 1/1 0.008/0.008 0.5/1 0.25/0.25 16/>512 0.5/0.5 
3e 128/128 32/32 64/64 >512 8/8 8/8 128/128 2/2 128/128 4/8 >512 64/64 
4e 4/4 4/4 2/2 >512 1/2 2/2 2/2 0.063/0.063 2/2 1/1 256/512 1/2 
Ciprofloxacin 0.25/0.5 1/1 0.25/0.25 128/128 0.032/0.063 0.032/0.032 0.5/0.5 0.008/0.008 0.25/0.5 0.125/0.125 8/>512 0.125/0.125 
3f 8/16 8/8 4/16 >512 2/2 4/4 32/>512 1/2 4/8 2/4 >512 32/32 
4f 8/8 32/128 8/8 >512 4/4 4/4 64/64 2/2 32/32 16/32 >512 64/64 
Sparfloxacin 0.125/0.25 0.125/0.125 0.125/0.125 32/32 0.063/0.063 0.016/0.032 0.125/0.125 0.004/0.008 0.063/0.063 0.032/0.032 0.25/128 0.5/1 
3g 8/16 8/8 8/16 >512 2/2 2/2 32/256 0.5/0.5 8/16 4/8 128/256 32/32 
4g 16/16 32/32 32/32 >512 32/32 0.25/0.5 128/128 4/4 16/16 4/8 128/256 64/64 
Gatifloxacin 0.25/0.25 0.125/0.125 0.125/0.25 8/16 0.032/0.063 0.016/0.032 0.25/0.25 0.008/0.008 0.125/0.125 0.063/0.063 1/256 0.25/0.5 
3h 4/8 4/4 4/4 512/512 0.5/0.5 4/8 64/128 0.5/0.5 8/8 1/4 32/256 32/32 
4h 8/8 8/8 2/8 >512 2/2 8/16 128/128 0.5/2 4/4 2/2 64/64 32/64 
Moxifloxacin 0.125/0.125 0.125/0.25 0.063/0.125 16/32 0.032/0.032 0.125/0.25 16/16 0.004/0.008 0.063/0.063 0.032/0.032 16/64 0.25/0.5 
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It should be emphasized that more hydrophilic Safirinium P hybrids 3 (log k from −0.5725 
to −0.2606) were much less active against the tested microorganisms than the corresponding less 
hydrophilic conjugates of Safirinium Q 4 (log k from −0.4434 to −0.07). These results may indicate 
strong correlation between antibacterial activity and lipophilic properties of the tested antibacterial 
agents. This observation stays in agreement with a general principle that antibacterial and 
antiproliferative activities of fluoroquinolones strongly depends on lipophilic profile, which condition 
their diffusion into bacterial [42,43] and human cancer cells [44,45]. In this context, increase in the 
overall lipophilic character of a quinolone derivative usually involves introduction of a bulky group 
at the N-4 position of piperazine, or more generally, at the C-7 position of the parent drug [42]. As 
Safirinium Q conjugates 4, incorporating large triazoloquinolinium moiety at the N-4 position of 
piperazine, are significantly less lipophilic than the free quinolones, and yet they retain antibacterial 
activity, the direct proportion between lipophilicity/C-7 bulkiness and biological potencies of these 
compounds may be questionable. This could be especially true for quinolones penetrating into 
nonhuman cells since, as mentioned earlier, most of the antibacterial agents demonstrate different 
properties than the drugs targeting human cells [12]. 
Microscopic images of E. coli cells treated with compound 4e and untreated cells used as a negative 
control are presented in Fig. 1. The cells incubated without the tested compound are regular-shaped 
and form short agglomerates (maximum 2–3 cells). However, the sample treated with conjugate 4e 
reveals significant reduction in cell number and morphological disorders. The bacterial cells are 
swelled and they do not separate after division forming long cords. Occurrence of cell aggregates 
may indicate disruption in cell division cycle. 
 
Figure 1. E. coli cells treated with compound 4e (left) and untreated (right), White Light Laser Confocal Microscope 





2.4. Examination of the modes of action 
The most promising compounds were selected for further evaluations by means of determination of 
their inhibitory activity against E. coli DNA gyrase supercoiling assay. Inhibitory ability was 
measured using commercial assay kit (Inspiralis Ltd, England). The results obtained are presented in 
Table 3 as residual activities (RA) of the enzyme at 10 and 1 μM of the tested compound, or as IC50 
values for the more active compounds (RA <35% at 10 μM). 
Table 3. Residual activities (RA) and IC50 values determined for compounds 
4b,d-f,h and ciprofloxacin against E. coli DNA gyrase. 
Compound RA in 10 μM [%] RA in 1 μM [%] IC50 [μM] 
4b 73 100 – 
4d 11 97 2.44 
4e 34 97 6.02 
4f 35 73 – 
4h 42 92 – 
Ciprofloxacin – 7 0.122 
 
 
   
Primary screening revealed that the tested compounds are potent DNA gyrase inhibitors. Compounds 
4d and 4e displayed considerable potencies with IC50 values in the low micromolar range, however 
their activity was weaker than that of bare ciprofloxacin. Moderate inhibitory activity against DNA 
gyrase combined with preserved in vitro antibacterial activity, as determined for the hybrid 
quaternary fluoroquinolones, may suggest that the studied compounds engage a complex mode of 
action. 
In order to investigate additional mode of action comprising bacterial membrane permeation 
characteristic for quaternary ammonium salts [46], permeabilization experiments were conducted. 
The ability of the obtained compounds to permeate E. coli ATCC 8739 inner membrane (IM) was 
evaluated as function of cytoplasmic β-galactosidase release, with bacteria grown in lactose 
containing medium, and determined optically at 415 nm. Assays were performed with 109 CFU/ml in 
10 mM Na-phosphate buffer, pH 7.5, containing 100 mM NaCl and 1.5 mM ONPG. In a preliminary 
test, we analysed permeation of the IM in a dose-dependent manner at 0.5–512 μg/mL (data not 
shown). Progressive release of the cytoplasmic β-galactosidase was observed when cells were treated 
with concentrations above bactericidal. Compound 4e at concentration 128 μg/mL caused 
considerable release of the enzyme into the medium within 90 min of incubation with cells after a lag 
time of about 10 min (Fig. S3, Supplemental Information). However, free ciprofloxacin in the same 
concentration also displayed permeabilization activity, nevertheless the effect was delayed and 




2.5. Antibiofilm activity 
Biofilms are surface-attached microbial community structures responsible for several chronic 
diseases that are difficult to treat. They represent predominant form of growth in vivo and can be 
formed by various microbial species from free-floating planktonic cells in response to several 
different factors including availability of nutrients and cellular recognition of attachment sites [47]. 
Bacterial biofilms are important from a clinical perspective since they cause numerous infections in 
humans, such us urinary tract infections, formation of dental plaque or infections in cystic fibrosis 
[48]. Moreover, these bacterial growth forms are often formed on the inert surfaces of implants such 
as prostheses, stents, cardiac valves, vascular grafts, urinary catheters, and intrauterine devices [49]. 
These heterogeneous and dynamic bacterial aggregates exhibit the ability to resist phagocytosis as 
well as the body's defence system due to mechanical strength and stability so that they are able to 
withstand the shear forces [50]. The presence of quaternary ammonium nitrogen atom possessing 
stable positive charge may facilitate efficient penetration of the complex extracellular matrix and 
uptake of drug molecules [51,52]. Considering these facts, the novel hybrid compounds that 
specifically target and inhibit the biofilm formation would constitute a valuable alternative to the 
traditional antibiotics. Compounds 4b,d, and e exhibiting good antibacterial activity were screened 
for their antibiofilm activity against biofilm-forming pathogens causing opportunistic respiratory, 
skin, and bone infections, P. aeruginosa ATCC 9027 and S. aureus 6538. Biofilm formation 
inhibition as well as mature biofilm degradation experiments were undertaken by means of total 
biomass crystal violet staning [53]. The results are shown in Fig. 2. All the tested compounds were  
 
Figure 2. The effects of fluoroquinolones against bacterial biofilms P. aeruginosa (left panel) and S. aureus 
(right panel): (top panel) prior to biofilm formation (pre-exposure) and (bottom panel) post-biofilm formation 




able to reduce the biofilm formation at the concentration of 1x MIC and 0.5x MIC towards both 
strains tested (pre-exposure). Compound 4e exhibited significant activity comparable to 
ciprofloxacin, especially towards S. aureus biofilm. Nevertheless, the novel conjugates displayed 
slightly weaker biofilm inhibition activity than the parent fluoroquinolones. Furthermore, derivative 
4e was found to be highly potent against P. aeruginosa in the mature biofilm degradation tests (post-
exposure). This compound showed notably higher activity than free ciprofloxacin. All the tested 
conjugates displayed anti-biofilm activities towards S. aureus, comparable to these assessed for the 
parent drugs. 
The results presented above have been validated by another research laboratory (Finland). Parallel 
pre-exposure and post-exposure S. aureus ATCC 25923 biofilm experiments with use of resazurin 
and crystal violet staining were performed. Rsaurin was used to measure biofilm viability, while 
crystal violet staining allowed total biomass measurments. 
Hybrids 4b,d,e were able to inhibit nearly 100% of biofilm viability within the concentration range 
of 2.5–20 μM when exposed to single-cell bacteria prior to the initiation of the biofilm formation 
process (Fig. S4). Total biomass of the formed biofilms was significantly decreased by the tested 
compounds at concentrations above 2.5 μM. However, very low concentrations (below 0.625 μM) of 
compounds 4b and 4d induced biofilm formation (Fig. S4). The conjugate 4e was found to be the 
most potent in post-exposure experiments inhibiting almost 100% of biofilm viability and nearly 50% 
of total biomass at the concentration of 40 μM (Fig. S5). Antibiofilm activity of this compound was 
similar or higher than its parent drug ciprofloxacin (Fig. S5). These results indicate that compound 
4e is able to penetrate extracellular matrix in mature biofilms more efficiently than the conventional 
antibiotic. 
 
2.6. Resistance development 
A number of various mechanisms can be involved in bacterial resistance development, eg. 
modifications of the antimicrobial molecule, prevention to reach the antibiotic target (such as 
decreasing penetration or actively extruding the antimicrobial compound), changes and/or bypass of 
target sites, and resistance due to global cell adaptive processes [54]. A common approach to evade 
fast developing bacterial resistance caused by spontaneous mutations in bacterial genome involves 
the use of hybrid drugs. 
The most active compounds were further selected to investigate the developing rate of bacterial 
resistance. The tested bacterial strains were exposed to sublethal concentrations of the analysed 
compounds for sustained passages. MIC values were recorded after 5, 10 and 15 passages (Fig. 3). 
The majority of conjugates displayed reduced likelihood of resistance development in comparison to 
the parent drugs. MICs increased slowly (only 1 or 2 dilution steps) upon 15 passages. Contrarily, 
faster development of resistance to parent quinolones was observed, as evidenced by rapid increase 






















Figure 3. Test of development of resistance to compounds 3g and 4b as well as their parent drugs by serial passages in 
liquid medium, MIC were recorded at the end of 5, 10 and 15 passage. 
For example, after 15 passages, P. vulgaris had developed a 4-fold increase in MIC for compound 3g 
(2 versus 0.5 μg/mL), while the relative MIC value of its parent drug, gatifloxacin, increased 32-fold 
(5 dilution steps). Development of S. epidermidis resistance to compound 3g was strongly delayed 
(approximately 2 times when compared to the parent drug). Also, enoxacin derivative 4b was found 
to be less susceptible to resistance development than its parent drug. MIC of enoxacin determined 
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after 10 passages of S. epidermidis increased 16-fold (4 dilution steps), while only 4-fold for 
compound 4b (2 dilution steps). The latter compound induced P. vulgaris resistance at a slower rate 
than the parent drug. 
2.7. Efflux evaluation 
The complete sequencing of bacterial genomes has revealed that E. coli contains 37 genes efflux 
pump transporters from five families: MFS (major facilitator superfamily), SMR (small multidrug 
resistance), RND (resistance nodulation cell division), ABC (ATP-binding cassette), and MATE 
(multidrug and toxic compound extrusion) [55]. AcrAB-TolC system, which belongs to RND family, 
is considered to be predominant efflux transporter in E. coli involved in multidrug resistance [56]. 
To evaluate susceptibility of E. coli efflux pump system to the obtained conjugates, compounds 4c-
e,g and 4c-e,g were additionally tested against E. coli ATCC 8739 in the presence of phenylalanine-
arginine β-naphthylamide (PAβN) at the concentration of 50 μg/mL (Table 4). PAβN is a preferential 
substrate for efflux pumps and it is routinely used in combination with antibiotics to assess their efflux 
vulnerability. The presence of PAβN increased the activity of ciprofloxacin derivatives 3e and 4e 
against E. coli 8-fold (MIC = 0.5 μg/mL) and 16-fold (MIC = 0.25 μg/mL), respectively, which 
suggests that these compounds are liable to bacterial efflux. For compounds 3c,d,g and 4c,d,g, 2-fold 
stronger inhibition was observed in the presence of PAβN. These results also indicate that the 
aforementioned compounds are to some extent susceptible to bacterial efflux. 
Table 4. MIC and MBC values determined for compounds 3a-h and 4a-h against E. coli ATCC 8739 
in the presence of PAβN at concentration of 50 μg/mL. 
Compound MIC/MBC [μg/mL] Activity increase 
3b 4/16 2-fold 
4b 0.5/1 2-fold 
3d 2/4 2-fold 
4d 0.125/0.25 2-fold 
3e 0.5/2 16-fold 
4e 0.25/0.5 8-fold 
3g 1/2 2-fold 
4g 0.125/0.5 2-fold 
 
Conjugates 3a-h and 4a-h display strong fluorescence due to the presence of Safirinium core 
(Supplemental Information, Table S1, Fig. S1). Compound 4e allowed for visualisation of E. coli 
cells by means of confocal microscopy (Supplemental Information, Fig. S2). No specific affinity for 
cell structures or accumulation in membranes were observed (data not shown). Fluorescence assay 
was used to further investigate the effects of efflux pump system [57]. Carbonyl cyanide m-
chlorophenylhydrazone (CCCP) has been used to study cellular accumulation in Gram-negative 
bacteria for a wide range of compounds [[58], [59], [60]] due to its ability to collapse the proton 
15 
 
motive force [61], which is the source of energy utilized by MFS, SMR, and RND pumps [55]. 
Cellular accumulation of the tested compound was measured in the presence or absence of CCCP. 
The fluorescence intensity of E. coli pretreated with 100 μM of CCCP (10 min, 37 °C) before 
incubation with 4e significantly increased compared to the untreated cells (Fig. 4). This result 
confirms that accumulation of the conjugate increases when efflux pumps are inhibited. Linear 










Figure 4. Fluorescence measurements of 4e cellular accumulation in E. coli ATCC 8739 assessed in the presence or 
absence of CCCP. 
 
2.8. Cytotoxicity evaluation 
The cytotoxicity of the prepared compounds 3a-h and 4a-h was examined in human embryonic 
kidney 293 cells (HEK 293) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) cell viability assay [62,63]. No reducing trends to the cell viability or changes in cell 
morphology were observed (data not shown). All the tested compounds were found to be non-toxic 
up to the concentration of 20 μM, which proves their potential for development of novel antibacterial 
agents. 
2.9. Molecular docking 
Docking studies were undertaken to rationalize the observed antibacterial activity and investigate the 
interactions of the newly prepared hybrids in the DNA gyrase catalytic site. Molecular modeling was 
performed using crystal structures of enzyme-DNA complexes obtained from the Protein Data Bank: 
DNA gyrase and topoisomerase IV from S. aureus and S. pneumoniae, respectively (PDB codes: 5cdq 
[64] and 3rae [65]). The obtained hybrids in deprotonated forms, as well as their parent drugs in 
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zwitterionic forms, were docked with use of OpenEye software [66]. All novel conjugates were able 
to bind in the fluoroquinolone-binding mode at both active sites of enzymes with docking scores 
comparable to the parent drugs. In almost all cases the carboxylate oxygen atoms of the quinolone 
core formed hydrogen bonds with serine side chain (Ser84 in S. aureus GyrA and Ser79 in 
S. pneumoniae ParC). Magnesium ion coordinated in the active centre of the enzyme was chelated 
with quinolone carboxylate and carbonyl oxygen atoms. The wedge-shaped quinolone core was 
stacked between base pairs at the DNA cleavage site and formed π- π interactions. Safirinium part of 
the conjugate adhered tightly in the binding pocket forming several van der Waals interactions. In 
general, for most compounds, quaternary nitrogen atom within triazolinium ring interacted via 
attractive charge with a glutamic acid residue of GyrB/ParE. For some compounds, additional 
hydrogen bonds were formed between the carboxylate group of the Safirinium part of the hybrid and 
basic side chains of amino acids, NH groups in protein backbone, or nucleobases. 
Compounds 4d,e and 3h were the most active conjugates within the series against S. aureus 
laboratory strains, both ATCC 6538 and MRSA N315, showing MIC values of 2 μg/mL for 4d and 
4 μg/mL for 4e and 3h. Moreover, these conjugates were highly active against S. aureus MRSA 6347 
clinical isolate with MIC values of 4, 2, and 8 μg/mL, respectively. The antibacterial activity of these 
compounds was confirmed by docking results with S. aureus DNA gyrase – the compounds were 
ranked higher than their parent drugs. Hybrid 3h reached the best binding scoring function rank 
among other conjugates with S. pneumoniae topoisomerase IV, which was consistent with MIC 
results: moxifloxacin derivative 3h was the most active conjugate from the obtained compounds 
against S. pneumoniae clinical isolate and exhibited MIC value of 32 μg/mL. However, the binding 
score as well as the biological activity (MIC value of 16 μg/mL) were slightly inferior compared to 
the parent drug, ie. bare moxifloxacin. 
Molecular structures of the highest scored poses of compound 3h docked in the active sites of 
analysed enzymes are presented in Figure 5. Hydrogen bond lengths between quinolone carboxylate 
and serine hydroxyl groups are in the range of 2.3–3.2 A, which is in agreement with corresponding 
lengths of original drugs found in crystal structures (2.8–3.1 A). Several hydrophobic and π-π as well 
as halogen (fluorine C6) interactions are formed between quinolone and DNA base rings in both 
active sites of enzymes. Positively charged nitrogen atom present in triazolinium ring is stabilized 
with Glu477 of S. aureus GyrB or Glu474 of S. pneumoniae ParE. Glu474 of S. pneumoniae ParE 
forms anion-π interactions with pyridine ring while Arg458 of S. aureus GyrB binds through a 
hydrogen bond with a carboxylate group of the pyridine ring. 
 
Figure 5. The highest scored poses of 3h (in magenta sticks) docked in the cleavage site 
of S. aureus DNA gyrase (up) and S. pneumoniae topoisomerase IV (down) active sites. 
Magnesium ion as orange sphere; subunits GyrA/ParC and GyrB/ParE in green and blue, 
respectively; original ligands form crystal structures, moxifloxacin and levofloxacin, 
respectively, in yellow sticks. For clarity, only relevant amino acids are presented. 
Hydrogen bonds are indicated as dotted lines. The Figure was prepared by PyMOL 
1.5.0.3. (For interpretation of the references to color in this figure legend, the reader is 





In summary, two series of novel (fluoro)quinolone-Safirinium P/Q dye hybrids were designed, 
synthesized and evaluated for their antibacterial activity. Unlike other zwitterionic quinolones, the 
obtained conjugates incorporate a permanent positive charge within the triazolinium ring and hence 
they lack typical pH dependent uncharged/deprotonated equilibrium that would condition their 
lipophilicity and facilitate passive diffusion through the lipid bilayer into the bacterial cells. The 
micellar electrokinetic chromatography experiments proved that the zwitterionic hybrids are 
significantly more hydrophilic than the parent quinolones. Yet at the same time, they retain 
antimicrobial, bactericidal, and antibiofilm activities against Gram positive and Gram-negative 
pathogenic bacteria. In particular, lomefloxacin (4d) and ciproflixacin (4e) Safirinium Q conjugates 
exhibited good potencies in inhibiting the growth of Staphylococcus aureus ATCC 6538, 
Staphylococcus aureus MRSA N315, Staphylococcus epidermidis ATCC 14990, Bacillus subtilis 
ATCC 6633, Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 9027, Proteus vulgaris 
NCTC 4635 Staphylococcus aureus MRSA 6347, Staphylococcus epidermidis MRSE 13199, and 
Serratia marcescens 12795. The results of in vitro enzymatic activity measurements using the E. coli 
DNA supercoiling assay showed that most active compounds 4d and 4e inhibit E. coli DNA gyrase 
in low micromolar range (IC50 values of 2.44 and 6.02 μM, respectively). Molecular docking studies 
indicate that the obtained compounds are able to interact with type II topoisomerases in 
fluoroquinolone-binding mode. Further experiments revealed that the hybrids do not display 
cytotoxicity towards human cells and to some extent they are susceptible to the efflux mechanism in 
Gram-negative bacteria. Furthermore, hybrid 4b displayed reduced susceptibility to development of 
resistance in comparison to the parent drug. Low cytotoxicity make the zwitterionic quinolones 
promising starting points for further optimization towards more potent and safer antibacterial agents. 
Accordingly, permanent C7 amine quaternization and reduced lipophilicity of quinolones would 
account for reduced distribution to the CNS and mammalian cells, as well as atypical 
pharmacokinetics. 
4. Experimental section 
4.1. General information 
Chemicals were obtained from Acros Organics or Sigma-Aldrich and used without further 
purification. Analytical TLC was performed on silica gel Merck 60 F254 plates (0.25 mm) with UV 
light visualisation. The 1H NMR spectra were obtained using Varian Mercury-VX 300 MHz 
spectrometer. 1H NMR data were internally referenced to TMS (0.0 ppm) or DMSO-d6 (2.5 ppm). 
The IR (KBr) spectra were recorded on Thermo Scientific Nicolet 380 FT-IR spectrometer. The mass 
spectra were recorded on Shimadzu single quadrupole LCMS 2010 eV mass spectrometer. Melting 
points were determined on a X-4 melting point apparatus with microscope and were uncorrected. 
Isoxazolones 1 and 2 were synthesized according to the previously described synthetic routes. Hence, 
substrate 1 was obtained via condensation of N-hydroxy-3-(hydroxyamino)-3-iminopropanamide 
with acetylacetone in the presence of piperidne [35], while 2 was synthesized through in multi-step 
procedure from aniline [36]. 
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4.2. Synthetic procedures 
4.2.1. General procedure for the synthesis of 8-carboxy-5,7-dimethyl-3H-spiro[ 
[1,2,4]triazolo[4,3-a]pyridine-2,1′-piperazin]-1′-ium chlorides (3a-h) 
4,6-Dimethylisoxazolo[3,4-b]pyridin-3(1H)-one (1) (0.150 g, 0.91 mmol), 35 wt % solution of 
formaldehyde (0.340 mL, 3.64 mmol) and the appropriate fluoroquinolone (0.61 mmol) or 
fluoroquinolone hydrochloride (0.61 mmol) and triethylamine (0.067 ml, 0.45 mmol) were dissolved 
in methanol (20 mL) and DMF (5 mL). The reaction mixture was heated for 1 h at 50 °C. The progress 
of the reaction was monitored with TLC (chloroform/methanol 9:1 v/v) and LC-MS 
(methanol/acetonitrile 1:1 v/v). After 12 h the precipitated product was filtered off and washed with 
acetone (3 x 3 mL). The filtrate was evaporated under reduced pressure and the product was 
recrystalized from methanol/dichloromethane (1:9) mixture for compounds 3a-e,g,h or isolated by 
HPLC purification (column SunFire Prep C18 OBD, 10 μm, 30 × 250 mm, Waters; elution phase: 
acetonitrile/water 5:95 with 0.1% acetic acid) for compound 3f. The obtained 5,7-dimethyl-3H-spiro[ 
[1,2,4]triazolo[4,3-a]pyridine-2,1′-piperazin]-9-ium-8-carboxylates were converted quantitatively 
into the hydrochlorides with methanolic solution of HCl. 
4.2.1.1. 8-Carboxy-4'-(6-carboxy-8-ethyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)-5,7-
dimethyl-3H-spiro[ [1,2,4]triazolo[4,3-a]pyridine-2,1′-piperazin]-1′-ium chloride (3a) 
Synthesized from pipemidic acid. Yield: 72% (0.233 g); mp 236–238 °C; IR (KBr): 3420, 3047, 1707, 
1626, 1543, 1473, 1444, 1371, 1264, 1183, 1118, 969, 815, 716, 607, 530 cm−1; 1H NMR (300 MHz, 
DMSO-d6): δ = 1.36 (t, J = 7.1 Hz, 3H, CH3), 2.25 (s, 3H, CH3), 2.32 (s, 3H, CH3), 3.86–3.95 (m, 4H, 
CH2), 4.23–3.28 (m, 2H, CH2), 4.45 (q, J = 7.1 Hz, 2H, CH2), 4.47–4.52 (m, 2H, CH2), 5.97 (s, 2H, 
CH2), 6.20 (s, 1H, CH), 9.02 (s, 1H, CH), 9.31 (s, H, CH), 13.29 (bs, 1H, OH), 14.65 (bs, 1H, OH); 
MS (ESI) m/z: 480 [M]+; elemental analysis calcd (%) for C23H26ClN7O5xH2O: C 51.72, H 5.29, N 
18.36; found C 51.39, H 5.02, N 18.08. 
4.2.1.2. 8-Carboxy-4'-(6-carboxy-8-ethyl-3-fluoro-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl)-5,7-
dimethyl-3H-spiro[ [1,2,4]triazolo[4,3-a]pyridine-2,1′-piperazin]-1′-ium chloride (3b) 
Synthesized from enoxacin. Yield: 36% (0.132 g); mp 209–210.5 °C; IR (KBr): 3413, 2987, 1711, 
1629, 1561, 1480, 1444, 1375, 1269, 1178, 1106, 1048, 972, 808, 744, 690, 600, 497 cm−1; 1H NMR 
(300 MHz, DMSO-d6): δ = 1.40 (t, J = 5.8 Hz, 3H, CH3), 2.25 (s, 3H, CH3), 2.32 (s, 3H, CH3), 3.80–
3.87 (m, 2H, CH2), 3.99–4.03 (m, 2H, CH2), 4.11–4.18 (m, 2H, CH2), 4.54 (q, J = 5.8 Hz, 2H, CH2), 
5.95 (s, 2H, CH2), 6. 20 (s, 1H, CH), 8.22 (d, JHF = 13.1 Hz, 1H, CH), 9.03 (s, 1H, CH), 13.12 (bs, 
1H, OH), 15.15 (bs, 1H OH); MS (ESI) m/z: 497 [M]+; elemental analysis calcd (%) for 
C24H26ClFN6O5x3.5H2O: C 48.36, H 5.58, N 14.10; found C 48.54, H 5.01, N 14.07. 
4.2.1.3. 8-Carboxy-4'-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)-5,7-dimethyl-
3H-spiro[ [1,2,4]triazolo[4,3-a]pyridine-2,1′-piperazin]-1′-ium chloride (3c) 
Synthesized from norfloxacin. Yield: 36% (0.212 g); mp 206–208 °C; IR (KBr): 3422, 2985, 1716, 
1628, 1564, 1483, 1386, 1272, 1177, 1029, 973, 806, 751, 694, 599, 499 cm−1; 1H NMR (300 MHz, 
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DMSO-d6): δ = 1.42 (t, J = 7.0 Hz, 3H, CH3), 2.24 (s, 3H, CH3), 3.32 (s, 3H, CH3), 3.81–3.88 (m, 8H, 
CH2), 4.63 (q, J = 7.0 Hz, 2H, CH2), 5.96 (s, 2H, CH2), 6.20 (s, 1H, CH), 7.34 (d, 
4JHF = 7.0 Hz, 1H, 
CH), 7.99 (d, 3JHF = 12.9 Hz, 1H, CH), 8.98 (s, 1H, CH); MS (ESI) m/z: 496 [M]
+; elemental analysis 
calcd (%) for C25H27ClFN5O5x6H2O: C 49.91, H 6.14, N 10.94; found: C 49.85, H 6.22, N 10.88. 
4.2.1.4. 8-Carboxy-4'-(3-carboxy-1-ethyl-6,8-difluoro-4-oxo-1,4-dihydroquinolin-7-yl)-2′,5,7-
trimethyl-3H-spiro[ [1,2,4]triazolo[4,3-a]pyridine-2,1′-piperazin]-1′-ium chloride (3d) 
Synthesized from lomefloxacin hydrochloride. Yield: 28% (0.101 mg); mp 219–222 °C; IR (KBr): 
3425, 3050, 2985, 2893, 1718, 1626, 1563, 1525, 1476, 1387, 1284, 1250, 1178, 1088, 1053, 806, 
740, 601 cm−1; 1H NMR (300 MHz, DMSO-d6): δ = 1.35 (d, J = 6.3 Hz, 3H, CH3), 1.46 (t, J = 6.8 Hz, 
3H, CH3), 2.25 (s, 3H, CH3), 2.38 (s, 3H, CH3), 3.56–3.63 (m, 1H, CH), 3.76–3.80 (m, 2H, CH2), 
3.81–3.84 (m, 2H, CH2), 3.97–4.03 (m, 2H, CH2), 4.57–4.62 (m, 2H, CH2), 5.97 (s, 2H, CH2), 6.18 
(s, 1H, CH), 7.94 (d, JHF = 11.9 Hz, 2H, CH), 8.97 (s, 1H, CH), 13.35 (bs, 1H, OH), 14.78 (bs, 1H, 
OH); MS (ESI) m/z: 528 [M]+; elemental analysis calcd (%) for C26H28ClF2N5O5x2H2O: C 52.05, H 
5.38, N 11.67; found: C 51.46, H 5.26, N 12.00. 
4.2.1.5. 8-Carboxy-4'-(3-carboxy-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)-5,7-
dimethyl-3H-spiro[ [1,2,4]triazolo[4,3-a]pyridine-2,1′-piperazin]-1′-ium chloride (3e) 
Synthesized from ciprofloxacin. Yield: 51% (0.187 g); mp 219–221 °C; IR (KBr): 3421, 2925, 2855, 
1716, 1629, 1561, 1491, 1466, 1269 cm-1; 1H NMR (300 MHz, DMSO-d6): δ = 1.19–1.21 (m, 2H, 
CH2), 1.19–1.21 (m, 2H, CH2), 2.25 (s, 3H, CH3), 2.33 (s, 3H, CH3), 3.81–3.89 (m, 8H, CH2), 4.06–
4.06 (m, 1H, CH), 5.96 (s, 2H, CH2), 6.20 (s, 1H, CH), 7.68 (d, 
4JHF = 7.6 Hz, 1H, CH), 7.98 (d, 
3JHF = 12.9 Hz, 1H, CH), 8.69 (s, 1H, CH), 15.09 (bs, 1H, OH); MS (ESI) m/z: 508 [M]+; elemental 




Synthesized from sparfloxacin. Yield: 26% (0.108 g); mp 209 °C (with decomposition); IR (KBr): 
3414, 2975, 2993, 1718, 1632, 1563, 1535, 1518, 1439, 1323, 1298, 1170, 1091, 1039, 508, 758 cm−1; 
1H NMR (300 MHz, CD3OD): δ = 1.17–1.24 (m, 4H, CH2), 1.43 (s, 3H, CH3), 1.45 (s, 3H, CH3), 2 
38* and 2.42* (s, 3H, CH3), 2.44* and 2.52* (s, 3H, CH3), 3.53–3.80 (m, 4H, CH2), 4.00–4.06 (m, 
1H, CH), 4.14–4.24 (m, 2H, CH), 5.91* and 5.96* (s, 2H, CH2), 6.20* and 6.23* (s, 1H, CH), 8.00 
and 8.01 (s, 1H, CH); MS (ESI) m/z: 569 [M]+; ]+; elemental analysis calcd (%) for 
C28H31ClF2N6O5x4H2O: C 49.67, H 5.81, N 12.41; found: C 49.60, H 5.43, N 12.20. 
4.2.1.7. 8-Carboxy-4'-(3-carboxy-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinolin-7-
yl)-2′,5,7-trimethyl-3H-spiro[ [1,2,4]triazolo[4,3-a]pyridine-2,1′-piperazin]-1′-ium chloride (3g) 
Synthesized from gatifloxacin. Yield: 35% (0.138 g); mp 195–197 °C; IR (KBr): 3422, 2937, 1720, 
1621, 1563, 1511, 1450, 1387, 1320, 1277, 1182, 1057, 937, 807, 599, 550, 478 cm−1; 1H NMR 
(300 MHz, DMSO-d6): δ = 1.05–1.14 (m, 4H, CH2), 1.27* and 1.35* (d, J = 6,2 Hz, 3H, CH3), 2.24* 
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and 2.25* (s, 3H. CH3), 2.36* and 2.41* (s, 3H. CH3), 3.62–3.78 (m, 4H, CH2), 3.83* and 3.86* (s, 
3H, OCH3), 4.05–4.08 (m, 1H, CH), 4.17–4.19 (m, 1H, CH), 5.81–6.08 (m, 2H, CH2), 7.82 (d, 
JHF = 12.0 Hz, 1H, CH), 8.72 (s, 1H, CH); MS (ESI) m/z: 552 [M]
+; elemental analysis calcd (%) for 
C28H31ClFN5O6x3H2O: C 52.38, H 5.81, N 10.91; found: C 52.20, H 5.45, N 10.88. 
4.2.1.8. 8-Carboxy-6'-(3-carboxy-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinolin-7-
yl)-5,7-dimethyl-2′,3′,4′,4a′,5′,6′,7′,7a′-octahydro-3H-spiro[ [1,2,4]triazolo[4,3-a]pyridine-2,1′-
pyrrolo[3,4-b]pyridin]-1′-ium chloride (3h) 
Synthesized from moxifloxacin hydrochloride. Yield: 0.085 g (20%); mp 190–191 °C; IR (KBr): 
3416, 3072, 2948, 2892, 1720, 1621, 1563, 1510, 1445, 1371, 1355, 1320, 1174, 1054, 1033, 806, 
484 cm−1; 1H NMR (300 MHz, DMSO-d6): δ = 0.93–0.98 (m, 1H, CH), 1.01–1.10 (m, 2H, CH2), 
1.16–1.21 (m, 2H, CH2), 1.60–1.67 (m, 2H, CH2), 1.86–2.03 (m, 2H, CH2), 2.17* and 2.24* (s, 3H, 
CH3), 2.29* and 2.83* (s, 3H, CH3), 3.56 (s, 3H, OCH3), 3.80–3.96 (m, 6H, CH2), 4.12–4.20 (m, 1H, 
CH2), 4.54–4.68 (m, 1H, CH), 5.80–6.08 (m, 2H, CH2), 6.14* and 6.16* (s. 1H, CH), 7.66* and 7.73* 
(d, JHF = 13.8 Hz, 1H, CH), 8.64* and 8.67* (s, 1H, CH); MS (ESI) m/z: 578 [M]
+; elemental analysis 
calcd (%) for C30H33ClFN5O6x5H2O: C 51.17, H 6.16, N 9.95; found: C 50.72, H 5.91, N 9.79. 
4.2.2. General procedure for the synthesis of 4-carboxy-1H-spiro[ [1,2,4]triazolo[4,3-
a]quinoline-2,1′-piperazin]-1′-ium chlorides (4a-h) 
Isoxazolo[3,4-b]quinolin-3(1H)-one (2) (0.100 g, 0.54 mmol), 35 wt % solution of formaldehyde 
(0.202 mL, 3.64 mmol) and the appropriate fluoroquinolone (0.54 mmol) or fluoroquinolone 
hydrochloride (0.54 mmol) and triethylamine (0.075 mL, 0.54 mmol) were dissolved in methanol 
(25 mL) at the room temperature. The progress of the reaction was monitored with TLC 
(chloroform/methanol 9:1 v/v) and LC-MS (methanol/acetonitrile 1:1 v/v). After 12 h the reaction 
mixture was evaporated under reduced pressure and the product was washed with acetone (3 x 3 mL). 
The obtained 1H-spiro[ [1,2,4]triazolo[4,3-a]quinoline-2,1′-piperazin]-11-ium-4-carboxylates were 
converted quantitatively into the corresponding hydrochlorides with methanolic solution of HCl. 
4.2.2.1. 4-Carboxy-4'-(6-carboxy-8-ethyl-5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-2-yl)-1H-
spiro[ [1,2,4]triazolo[4,3-a]quinoline-2,1′-piperazin]-1′-ium chloride (4a). Synthesized from 
pipemidic acid 
Yield: 73% (0.235 g); mp 231–232.5 °C; IR (KBr): 3418, 2925, 2854, 1719, 1621, 1572, 1541, 1516, 
1443, 1369, 1261, 1212, 1170, 1117, 816, 592 cm−1; 1H NMR (300 MHz, DMSO-d6): δ = 1.38 (t, 
J = 7.1 Hz, 3H, CH3), 4.01–4.07 (m, 4H, CH2), 4.36–4.50 (m, 4H, CH2), 4.47 (q, J = 7.1 Hz, 2H, CH2), 
6.05 (s, 2H, CH2), 7.25 (d, J = 7.9 Hz, 1H, CH), 7.39 (t, J = 7.9 Hz, 1H, CH), 7.82 (t, J = 7.9 Hz, 1H, 
CH), 8.01 (d, J = 7.9 Hz, 1H, CH), 8.75 (s, 1H, CH), 9.0 (s, 1H, CH), 9.33 (s, 1H, CH); MS (ESI) 
m/z: 502 [M]+; elemental analysis calcd (%) for C25H24ClN7O5x3.5H2O: C 49.96, H 5.20, N 16.31; 
found: C 49.48, H 4.95, N 16.21. 
4.2.2.2. 4-Carboxy-4'-(6-carboxy-8-ethyl-3-fluoro-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl)-1H-
spiro[ [1,2,4]triazolo[4,3-a]quinoline-2,1′-piperazin]-1′-ium chloride (4b) 
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Synthesized from enoxacin. Yield: 74% (0.243 g); mp 227.5–229.5 °C; IR (KBr): 3418, 2925, 1711, 
1626, 1573, 1549, 1477, 1448, 1378, 1272, 1210, 1168, 1105, 808, 745, 592, 499, 459 cm−1; 1H NMR 
(300 MHz, DMSO-d6): δ = 1.41 (t, J = 7.3 Hz, 3H, CH3), 3.99–4.13 (m, 4H, CH2), 4.28–4.32 (m, 4H, 
CH2), 4.57 (q, J = 7.3 Hz, 2H, CH2), 6.04 (s, 2H, CH2), 7.24 (d, J = 8.2 Hz, 1H, CH), 7.39 (t, 
J = 8.2 Hz, 1H, CH), 7.82 (t, J = 8.2 Hz, 1H, CH), 8.01 (d, J = 8.2 Hz, 1H, CH), 8.24 (d, JHF = 12.9 Hz, 
1H, CH), 8.75 (s, 1H, CH), 9.04 (s, 1H, CH), 9.49 (bs, 1H, OH), 15.14 (bs, 1H, OH); MS (ESI) m/z: 
519 [M]+; elemental analysis calcd (%) for C26H24ClFN6O5x3H2O: C 51.28, H 4.97, N 13.80; found: 
C 51.02, H 4.65, N 13.80. 
4.2.2.3. 4-Carboxy-4'-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)-1H-spiro[ 
[1,2,4]triazolo[4,3-a]quinoline-2,1′-piperazin]-1′-ium chloride (4c) 
Synthesized from norfloxacin. Yield: 93% (0.313 g); mp 244–245 °C; IR (KBr): 3423, 2979, 1715, 
1625, 1573, 1548, 1460, 1389. 1270, 1215, 750 cm−1; 1H NMR (300 MHz, DMSO-d6): δ = 1.44 (t, 
J = 7.1 Hz, 3H, CH3), 3.84–3.91 (m, 4H, CH2), 3.97–4.20 (m, 4H, CH2), 4.65 (q, J = 7.1 Hz, 2H, CH2), 
6.03 (s, 2H, CH2), 7.22 (d, J = 8.2 Hz, 1H, CH), 7.37–7.42 (m, 2H, CH), 7.82 (t, J = 8.2 Hz, 1H, CH), 
8.00 (d, J = 5.3 Hz, 1H, CH), 8.03 (s, 1H, CH), 8.75 (s, 1H, CH), 8.99 (s, 1H, CH); MS (ESI) m/z: 
518 [M]+; elemental analysis calcd (%) for C27H25ClFN5O5x4H2O: C 51.80, H 5.31, N 11.19; found: 
C 51.58, H 4.94, N 11.22. 
4.2.2.4. 4-Carboxy-4'-(3-carboxy-1-ethyl-6,8-difluoro-4-oxo-1,4-dihydroquinolin-7-yl)-2′-methyl-
1H-spiro[ [1,2,4]triazolo[4,3-a]quinoline-2,1′-piperazin]-1′-ium chloride (4d) 
Synthesized from lomefloxacin hydrochloride. Yield: 86% (0.295 g); mp 276 °C (with 
decomposition); IR (KBr): 6045, 3139, 3048, 1723, 1621, 1573, 1525, 1455, 1395, 1329, 1253, 1206, 
1088, 1050, 1021, 932, 807, 739 cm−1; 1H NMR (300 MHz, DMSO-d6): δ = 1.29 (t, J = 6.5 Hz, 3H, 
CH3), 1.44–1.47 (m, 3H, CH3), 3.71–3.87 (m, 4H, CH2), 3.94–4.00 (m, 1H, CH), 4.07–4.14 (m, 2H, 
CH2), 4.57–4.60 (m, 2H, CH2), 5.86–6.21 (m, 2H, CH2), 7.40 (d, J = 7.6 Hz, 1H, CH), 7.80–7.97 (m, 
3H, CH), 8.01 (d, J = 8.2 Hz, 1H, CH), 8.73 (s, 1H, CH), 8.95 (d, JHF = 8.2 Hz, 1H, CH) 8.97 (s, 1H, 
CH), 9.81 (bs, 1H, OH), 9.69 (bs, 1H, OH); MS (ESI) m/z: 550 [M]+; elemental analysis calcd (%) 
for C28H26ClF2N5O5x3H2O: C 52.54, H 5.04, N 10.94; found: C 52.36, H 5.19, N 10.82. 
4.2.2.5. 4-Carboxy-4'-(3-carboxy-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)-1H-
spiro[ [1,2,4]triazolo[4,3-a]quinoline-2,1′-piperazin]-1′-ium chloride (4e) 
Synthesized from ciprofloxacin. Yield: 91% (0.307 g); mp 249–251 °C; IR (KBr): 3421, 3059, 1717, 
1625, 1573, 1547, 1492, 1459, 1268, 1217, 1170, 952, 806, 748, 707, 593, 462 cm−1; 1H NMR 
(300 MHz, DMSO-d6): δ = 1.18–1.23 (m, 2H, CH2), 1.28–1.37 (m, 2H, CH2), 3.54–3.58 (m, 1H, CH), 
4.88–4.90 (m, 4H, CH2), 4.02–4.06 (m, 2H, CH2), 4.18–4.22 (m, 2H, CH2), 6.05 (s, 2H, CH2), 7.24 
(d, J = 8.2 Hz, 1H, CH), 7.39 (t, J = 8.2 Hz, 1H, CH), 7.72 (d, 4JHF = 7.6 Hz, 1H, CH), 7.82 (t, 
J = 8.2 Hz, 1H, CH), 7.99 (d, 3JHF = 12.9 Hz, 1H, CH), 8.02 (d, J = 8.2 Hz, 1H, CH), 8.69 (s, 1H, CH), 
8.75 (s, 1H, CH), 9.55 (bs, 1H, OH), 15.09 (bs, 1H, OH); MS (ESI) m/z: 530 [M]+; elemental analysis 




carboxy-2′,6′-dimethyl-1H-spiro[ [1,2,4]triazolo[4,3-a]quinoline-2,1′-piperazin]-1′-ium chloride 
(4f) 
Synthesized from sparfloxacin. Yield: 86% (0.331 g); mp 240–241 °C; IR (KBr): 3443, 2985, 1715, 
1626, 1573. 1519, 1439, 1323, 1299, 1208, 1167, 1088, 758 cm−1; 1H NMR (300 MHz, DMSO-d6): 
δ = 1.13 (d, J = 5.9 Hz, 4H, CH2), 1.26* and 1.30* (d, J = 6.4 Hz, 6H, CH3), 3.6 (bs, 2H, NH2), 3.73 
(d, J = 6.5 Hz, 4H, CH2), 4.02–4.04* and 4.33–4.34* (m, 2H, CH), 4.18–4.25 (m, 1H, CH), 6.07* and 
6.13* (s, 2H, CH2), 7.40 (t, J = 8.2 Hz, 1H, CH), 7.44 (d, J = 8.2 Hz, 1H, CH), 7.84 (t, J = 8.2 Hz, 1H, 
CH), 8.00 (d, J = 8.2 Hz, 1H, CH), 8.54 (s, 1H, CH), 8.73 (s, 1H, CH); MS (ESI) m/z: 591 [M]+; 
elemental analysis calcd (%) for C30H29ClF2N6O5x5H2O: C 50.25, H 5.48, N 11.72; found: C 50.01, 
H 5.01, N 11.46. 
4.2.2.7. 4-Carboxy-4'-(3-carboxy-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinolin-7-
yl)-2′-methyl-1H-spiro[ [1,2,4]triazolo[4,3-a]quinoline-2,1′-piperazin]-1′-ium chloride (4g) 
Synthesized from gatifloxacin. Yield: 91% (0.351 g); mp 227–229 °C; IR (KBr): 3417, 2942, 1721, 
1620, 1573, 1546, 1510, 1452, 1391, 1320, 1194, 1168, 1059, 807 cm−1; 1H NMR (300 MHz, 
DMSO-d6): δ = 1.06–1.11 (m, 2H, CH2), 1.13–1.15 (m, 2H, CH2), 1.31* and 1.36* (d, J = 6.4 Hz, 3H, 
CH3), 3.61–3.82 (m, 4H, CH2), 3.88* and 3.90* (s, 3H, OCH3), 3.94–4.02 (m, 1H, CH), 4.08–4.12 
(m, 1H, CH), 4.19–4.29 (m, 2H, CH2), 5.85–6.21 (m, 2H, CH2), 7.15–7.43 (m, 2H, CH), 7.80–7.87 
(m, 2H, CH), 8.01 (d, J = 7.6 Hz, 1H, CH), 8.73 (s, 1H, CH), 8.74 (s, 1H, CH); MS (ESI) m/z: 574 
[M]+; elemental analysis calcd (%) for C30H29ClFN5O6x6H2O: C 50.18, H 5.75, N 9.75; found: C 
50.06, H 5.79, N 9.56. 
4.2.2.8. 4-Carboxy-6'-(3-carboxy-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinolin-7-
yl)-2′,3′,4′,4a′,5′,6′,7′,7a′-octahydro-1H-spiro[ [1,2,4]triazolo[4,3-a]quinoline-2,1′-pyrrolo[3,4-
b]pyridin]-1′-ium chloride (4h) 
Synthesized from moxifloxacin hydrochloride. Yield: 84% (0.383 g); mp 208.5–210.5 °C; IR (KBr): 
3421, 2934, 2891, 1718, 1620, 1573, 1558, 1508, 1442, 1355, 1319, 1211, 1168. 1111, 1053, 964, 
941, 889, 806, 760, 594 cm−1; 1H NMR (300 MHz, DMSO-d6): δ = 0.90–0.98 (m, 1H, CH), 1.01–1.06 
(m, 2H, CH2), 1.73–1.77 (m, 2H, CH2), 1.96–1.96 (m, 2H, CH2), 2.08–2.17 (m, 2H, CH2), 3.57 (s, 
3H, OCH3), 3.80–3.90 (m, 4H, CH2), 4.07–4.14 (m, 2H, CH2), 4.22–4.33 (m, 1H, CH), 4.69–4.77 (m, 
1H, CH), 5.85–6.33 (m, 2H, CH2), 7.30–7.36 (m, 2H, CH), 7.65* and 7.71* (d, JHF = 13.8 Hz, 1H, 
CH), 7.80 (t, J = 8.2 Hz, 1H, CH), 7.97 (t, J = 8.2 Hz, 1H, CH), 8.63 (s, 1H, CH), 8.67* and 8.72* (s, 
1H, CH); MS (ESI) m/z: 600 [M]+; elemental analysis calcd (%) for C32H31ClFN5O6x4H2O: C 54.28, 
H 5.55, N 9.89; found: C 54.93, H 5.47, N 9.89. 
4.3. MEKC analysis 
All micellar electrokinetic chromatography (MECK) experiments were carried out with a P/ACE 
MDQ plus system (Sciex, Framingham, MA, USA) equipment on photodiode array detector (PDA) 
and controlled by 32 Karat software (version 10.2). The uncoated fused silica capillaries (50 mm i.d., 
Polymicro Technologies, West Yorkshire, UK) of 60 cm total length and 50.2 cm effective length 
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was used. The capillary was rinsed with 0.1 M NaOH for 30 min, ultrapure water for 10 min and BGE 
for 30 min. Before each analysis the capillary was conditioned with BGE for 2 min. Applied pressure 
for all rinsing operations was 50 psi. The analytes were dissolved in BGE at concentration of 
100 μg/ml with addition of quinine (micelles marker) and DMSO (EOF marker). Samples were 
hydrodynamically injected at 5 psi for 5 s. The separations were performed by applying voltage of 
20 kV with positive polarity and constants temperatures at 25 ± 0.1 °C. The BGE consisted of aqueous 
solution of 50 mM SDS and 120 mM HEPES - 100 mM Tris buffer of pH 7.4. Detection was carried 
out at 200, and 280 nm with 8 Hz probing frequency. The logarithm of retention factor log k MECK 
was calculated using equation introduced by Terabe and co-workers [37]: 
4.4. Biological activity 
4.4.1. Bacterial strains and growth conditions 
Antibacterial activity was tested using eight reference (Staphylococcus aureus ATCC 6538, 
Staphylococcus aureus MRSA N315, Staphylococcus epidermidis ATCC 14990, Enterococcus hirae 
ATCC 1052, Bacillus subtilis ATCC 6633, Escherichia coli ATCC 8739, Pseudomonas aeruginosa 
ATCC 9027, Proteus vulgaris NCTC 4635) and four clinical strains (Staphylococcus aureus MRSA 
6347, Staphylococcus epidermidis MRSE 13199, Streptococcus pneumoniae, Serratia marcescens 
12795). Clinical strains were isolated from patients hospitalized in St. Wojciech Adalbert Specialist 
Hospital in Gdańsk (Independent Public Health Care Facility in Gdańsk, Poland). The other 
microorganisms were sourced from the American Type Culture Collection (ATCC), University 
Boulevard Manassas, VA, USA. 
All bacterial strains were cultured in MH (Muller Hinton) medium with the only exception of 
Enterococcus hirae strain, which was cultured in BHI (Brain Heart Infusion). Media were purchased 
from BioMaxima Polska. 
4.4.2. Determination of antibacterial activity 
The minimum inhibitory concentrations (MIC) and the minimum bactericidal concentrations (MBC) 
of commercial drugs and hybrid agents were determined by microbroth dilution method according to 
the EUCAST (European Committee for Antimicrobial Susceptibility Testing) [67] and CLSI 
(Clinical and Laboratory Standards Institute) [68] reference procedure. The assays were carried out 
against selected reference and clinical strains Gram-positive and Gram-negative bacteria (Table 2). 
The inoculum size was 1 x 105 to 5 x 105 CFU/ml. Stock solutions and dilution series of the all test 
compounds were prepared in 100% dimethyl sulfoxide (DMSO). Solutions of the test substances 
were diluted 50-fold in a proper medium, MH or BHI broth, with the bacterial suspension in 96-well 
plates. The DMSO final concentration in the assays did not exceed 2.0%. The final concentration of 
the tested compounds ranged from 512 to 0.004 μg/mL. Microplates were incubated at 37 °C for 48 h. 
The MIC was considered as the lowest concentration of compound that prevented visible growth of 
bacteria. Additionally, 10 μL of suspension from each well without growth were transferred into agar 
plates to control bacterial viability. Inoculated plates were incubated at 37 °C. After 48 h bacterial 
growth was observed, defining MBC as the ability of the bacteria with inhibited growth to survive. 
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The presented results are representative of at least three independent measurements each made in 
triplicate. 
4.4.3. In vitro inhibitory activity screening and determination of IC50 values on E. coli DNA 
gyrase 
The assay for determining IC50 values (Inspiralis) was performed on black streptavidin-coated 96-
well microtiter plates (Thermo Scientific Pierce). The plate was first rehydrated with the wash buffer 
supplied (20 mM Tris-HCl pH 7.6, 137 mM NaCl, 0.01% w/v BSA, 0.05% v/v Tween 20). 
Biotinylated oligonucleotide in wash buffer was immobilized onto the wells. The excess of 
oligonucleotide was then washed off and the enzyme assay carried out in the wells (5 min). The final 
reaction volume of 30 μL in buffer (35 mM Tris-HCl pH 7.5, 24 mM KCl, 4 mM MgCl2, 2 mM DTT, 
1.8 mM spermidine, 1 mM ATP, 6.5% w/v glycerol, 0.1 mg/mL albumin) contained 1.5 U of DNA 
gyrase from E. coli, 0.75 μg of relaxed pNO1 plasmid, and 3 μL of inhibitors solution in 10% DMSO 
and 0.008% Tween® 20. The reactions were incubated for 30 min at 37 °C and, after addition of the 
TF buffer (50 mM NaOAc pH 5.0, 50 mM NaCl, and 50 mM MgCl2), which terminated the enzymatic 
reaction, for another 30 min at room temperature to allow triplex formation (biotin–oligonucleotide–
plasmid). The unbound plasmid was then washed off using TF buffer, and a solution of SybrGOLD 
stain in T10 buffer (10 mMTris-HCl pH 8.0 and 1 mM EDTA) was added. After mixing, the 
fluorescence (excitation 485 nm, emission 535 nm) was read using a BioTek Synergy H4 microplate 
reader. Preliminary screening was performed at inhibitor concentrations of 10 and 1 μM. IC50 was 
determined with seven concentrations of the inhibitors. IC50 values were calculated using GraphPad 
Prism software and represent the concentration of inhibitor where the residual activity of the enzyme 
is 50% in three independent measurements; the final result is given as their average value. 
Ciprofloxacin was used as a positive control. 
4.4.4. Determination of antibiofilm activity 
4.4.4.1. Biofilm inhibition tests 
The overnight bacterial cultures were diluted 1:10 with the TSB (Tryptic Soy Broth, BioMaxima 
Polska). The 20 μL of inoculum was transferred into 96-well microtiter plates, with 166 μL of fresh 
TSB and 4 μL of appropriate compound to obtain a concentration corresponding to 1/2MIC, MIC, 
2xMIC, 4xMIC. The growth control of bacteria in medium without compounds were also included in 
the test. After incubation at 37 °C for 24 h, the supernatants were removed and the plates were washed 
three times with 200 μL sterile normal saline. The surface-attached cells were stained with 200 μL of 
0.1% crystal violet for 10 min. The plates were washed 3 times with distilled water and dye was re-
eluted with 100% ethanol. Plates were shaken gently, until all crystal violet was dissolved. 
Absorbance was measured at 570 nm in Tecan Infinite 200 (Tecan, Männedorf CH) plate reader. 
4.4.4.2. Biofilm degradation tests 
The overnight bacterial cultures were diluted 1:10 with the TSB. The 20 μL of inoculum was 
transferred into well microtiter plates, with 170 μL of fresh TSB and incubated at 37 °C for 24 h for 
biofilm formation. The culture supernatant was discarded and the wells were washed 2 times with 
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sterile normal saline to remove nonadherent cells. Then, the wells were filled with combination of 
fresh TSB medium, compound and bacterial suspension. After incubation for the next 24 h, a 
procedure for rinsing and staining the biofilm with crystal violet was performed. Absorbance of 
dissolved dye was measured at 570 nm in Tecan Infinite 200 plate reader. 
4.4.5. Efflux pump activity assays 
Determination of MIC and MBC against E. coli ATCC 8739 were performed as described above with 
addition of phenylalanine-arginine β-naphthylamide (PAβN) at final concentration of 50 μg/mL. 
Fluorescence measurements of cellular accumulation were performed as follows, according to the 
literature protocol [53]: bacteria E. coli ATCC 8739 were cultured in LB at 37 °C overnight. A sample 
of a culture was diluted 50-fold in LB and incubated at 37 °C for 1.5–2 h. The resultant mid-log phase 
cultures were harvested at 4000 rpm for 25 min, washed once with PBS (4000 rpm, 15 min), and 
resuspended in PBS to an OD600 of 2. Bacteria were treated with 100 μM of CCCP (Sigma Aldrich) 
at 37 °C for 10 min and then with the tested compound at the desired concentration at 37 °C for 0.5 h, 
washed with 1 mL of cold water 4 times (13 000 rpm, 4 °C, 7 min). To avoid background noise, the 
flat-bottom black 96-well microplates (Greiner Bio-One, Germany) were used for fluorescence 
intensity measurements. Bacteria cell pellets were transferred into 96-well plate in final volume of 
150 μL. The plate reader TECAN Infinite M200 PRO (Switzerland) was used to read the fluorescence 
intensity with excitation and emission wavelengths of 340 and 450 nm, respectively. 
4.4.6. Induction of drug resistance 
Initial MIC was taken as a reference point for experimental induction for drug resistance. Selected 
strains were tested by the serial passages in a medium supplemented with selected fluoroquinolones 
or new compounds below their active concentrations (0.5 MIC, 0.25 MIC). MIC values of compounds 
after each five, ten and fifteen passages were determined by a broth microdilution method (see above). 
4.4.7. In vitro cytotoxicity assays 
The cytotoxicity was determined by the standard colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay [69]. The assessment of cell population growth is based 
on the capability of living cells to reduce the yellow product MTT to a blue/purple product, formazan, 
by a reduction reaction occurring in the mitochondria catalysed by dehydrogenase enzyme. The 
adherent HEK-293 cells were seeded into 96-well plates (2 × 104 cells/well) and cultured for 24 h at 
37 °C in a humidified atmosphere of 5% CO2 allowing to attach. A solutions of the tested compounds 
in DMSO at desired concentrations were freshly prepared. The cells were then exposed to various 
concentrations of compounds (2 μL of DMSO solution per 200 μL of final volume). Cells untreated 
with compounds containing 0.5% DMSO and medium without cells were used as negative control 
and blank control, respectively. After 72 h of the exposure to tested compounds 20 μL MTT solution 
(4 mg/mL) per well was added to each cultured medium, which was incubated for another 4 h in the 
CO2 incubator. The medium was removed to afford the resulting formazan crystals followed by 
dissolving in 75 μL DMSO and the plates were shaken for 30 min at room temperature. The optical 
density (OD) of each well was measured at wavelength of 540 nm with a microplate reader and the 
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percentage of cell growth was calculated. All samples were tested at two independent experiments, 
each done in triplicate. 
4.5. Molecular modeling 
4.5.1. Ligand and protein preparation 
The structures of compounds were prepared in Online SMILES Translator and Structure File 
Generator [70] taking account the chirality on quaternary nitrogen atom and appropriate protonation 
states of compounds. The structures were converted into SMILES forms and diastereoisomers of 
chiral compounds were generated using FLIPPER tool in OMEGA software [71]. A library of 
conformers was generated with use of OMEGA using default settings, which resulted in a maximum 
of 200 conformers per ligand [72]. 
For docking with HYBRID software [73], proteins were prepared using MAKE RECEPTOR 
[66,73,74]. The grid box around the ligand bound in the crystal structure was generated automatically 
and was not adjusted, which resulted in grid box sizes of 4645 and 4431 Å for S. aureus DNA gyrase 
and S. pneumoniae topoisomerase IV, respectively. For “Cavity detection” slow and effective 
“Molecular” method was used for detection of binding sites. Inner and outer contours of the grid box 
were also calculated automatically using “Balanced” settings for “Site Shape Potential” calculation, 
which again resulted in different outer contour sizes depending on the bound ligand, 1459 and 1262 Å 
for S. aureus DNA gyrase and S. pneumoniae topoisomerase IV, respectively. The inner contours 
were disabled. Magnesium ion and Ser79 (S. aureus GyrA)/Ser84 (S. pneumoniae ParC) were used 
as constraints for docking calculations. 
4.5.2. Ligand docking 
The conjugates were docked using HYBRID [73,74]. Docking resolution was set to high; other 
settings were set as default. Ten docking solutions were inspected visually and the best ranked 
HYBRID-calculated conformation was used for analysis and representation. 
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